News

No benefit from added trabectedin for STS patients


 

FROM JOURNAL OF CLINICAL ONCOLOGY

References

When trabectedin was administered to soft tissue sarcoma (STS) patients receiving doxorubicin, neither progression-free nor overall survival significantly improved, investigators found.

In addition, patients who received both drugs were significantly more likely to experience adverse events.

“The combination of trabectedin plus doxorubicin did not show superiority over doxorubicin alone as first-line treatment of advanced STS patients, at least under this schedule. Moreover, the experimental arm was significantly more toxic than the control arm, especially regarding thrombocytopenia, vomiting, liver toxicity, and asthenia,” wrote Dr. Javier Martin-Broto of the Virgen del Rocio Hospital and Biomedicine Institute, Seville (Spain) and his associates (J Clin Oncol. 2016. doi: 10.1200/JCO.2015.65.3329).

Of 115 adult patients with advanced nonresectable or metastatic STS, 59 received doxorubicin only, 55 received both doxorubicin and trabectedin, and one patient was not treated. In the experimental group, doxorubicin was administered before trabectedin. Both the experimental and control groups underwent six cycles of their respective drug regime unless disease progression or unacceptable toxicity was observed.

A Cox proportional hazard regression model revealed that the progression-free survival was not significantly higher among patients receiving trabectedin and doxorubicin compared to patients only receiving doxorubicin (5.7 months vs. 5.5 months; hazard ratio, 1.16; 95% confidence interval, 0.79-1.71; P = .45). Overall survival was also not significantly different between the groups (13.3 months vs. 13.7 months; HR, 1.21; 95% CI, .77-1.92, P = .41).

However, compared with patients who only received doxorubicin, patients who received both trabectedin and doxorubicin experienced significantly more adverse events such as grade 3 or 4 thrombocytopenia (2% vs. 18%, P = .016), grade 3 or 4 liver toxicity (12% vs. 29%, P = .002), AST (0% vs. 8%, P = .007), ALT (0% vs. 19%, P less than .001), and grade 3 or 4 asthenia (4% vs. 25%, P = .002).

jcraig@frontlinemedcom.com

On Twitter @jess_craig94

Recommended Reading

HDAC inhibition may reverse anthracycline resistance in patients with sarcoma
MDedge Hematology and Oncology
PFS a surrogate for overall survival in soft tissue sarcoma trials
MDedge Hematology and Oncology
Trabectedin found to benefit patients with uterine leiomyosarcoma
MDedge Hematology and Oncology
Bone sarcomas are not just for kids
MDedge Hematology and Oncology
CT of chest, extremity effective for sarcoma follow-up
MDedge Hematology and Oncology
Better sarcoma outcomes at high-volume centers
MDedge Hematology and Oncology
Feds advance cancer moonshot with expert panel, outline of goals
MDedge Hematology and Oncology
Older patients with soft tissue sarcoma may receive greater benefit from RT
MDedge Hematology and Oncology
Targeting gene rearrangements shows promise in early study
MDedge Hematology and Oncology
FDA grants priority review of olaratumab for advanced sarcoma
MDedge Hematology and Oncology